GO:0160224 3-demethoxyubiquinone 3-hydroxylase (NADH) activity

GO:0160224, 3-demethoxyubiquinone 3-hydroxylase (NADH) activity, is a molecular function annotation describing an enzymatic step in the mitochondrial biosynthesis of ubiquinone (coenzyme Q). The reaction converts a 5-methoxy-2-methyl-3-(all-trans-polyprenyl)benzoquinone intermediate into a 3-demethylubiquinone while consuming NADH and O2 and releasing NAD+ and H2O. This activity is therefore part of the terminal modification phase of the coenzyme Q pathway, in which the benzoquinone ring is further functionalized to reach the mature ubiquinone molecule. For researchers, GO:0160224 matters because coenzyme Q is an essential electron carrier in the mitochondrial respiratory chain and a lipid-soluble antioxidant. When coenzyme Q biosynthesis is impaired, affected individuals can present with mitochondrial disease phenotypes, including the nuclear gene-encoded Leigh syndrome spectrum. Understanding the precise catalytic step described by this GO term helps connect genotype to biochemical phenotype and supports the interpretation of variants found in patients with suspected mitochondrial disorders. This article summarizes the QuickGO definition, the reaction chemistry, the genes and proteins that participate in or support this activity, and the experimental models used to study it. All statements are based on the verified literature and the QuickGO entry for GO:0160224.

In plain terms, GO:0160224 describes an enzyme activity that adds a hydroxyl group to a specific ubiquinone precursor using NADH as the electron donor and oxygen as the acceptor. The official definition states: Catalysis of the reaction: a 5-methoxy-2-methyl-3-(all-trans-polyprenyl)benzoquinone + NADH + O2 = a 3-demethylubiquinone + NAD+ + H2O. The synonym 5-methoxy-2-methyl-3-(all-trans-polyprenyl)benzoquinone,NADH:oxygen oxidoreductase (5-hydroxylating) activity captures the same chemistry. This is a molecular_function term, not a cellular component or a biological process, so it should be used to annotate the catalytic capability of a gene product rather than a pathway or location.

GO:0160224 is important because it defines a specific catalytic step in coenzyme Q biosynthesis, a pathway required for mitochondrial respiration and antioxidant defense. Impaired coenzyme Q biosynthesis is a recognized cause of mitochondrial disease, including the nuclear gene-encoded Leigh syndrome spectrum, and the biochemical characterization of each step helps explain patient phenotypes and guide variant interpretation. For researchers, this term provides a precise annotation target when assigning function to candidate genes, designing enzymatic assays, or interpreting multi-omics data from mitochondrial disease models.

The following genes and proteins are relevant to coenzyme Q biosynthesis and mitochondrial function, and they provide context for studying GO:0160224.

The activity described by GO:0160224 operates within the coenzyme Q biosynthetic pathway, which is responsive to mitochondrial energy demand and oxidative stress. While specific transcriptional or post-translational regulators of this exact step are not fully detailed in the verified literature, the pathway as a whole is essential for mitochondrial function, and its disruption leads to disease phenotypes such as the nuclear gene-encoded Leigh syndrome spectrum. Researchers should consider pathway-level regulation, including substrate availability, oxygen tension, and NADH/NAD+ ratio, when designing experiments.

Defects in coenzyme Q biosynthesis, including steps related to GO:0160224, are among the nuclear gene-encoded causes of Leigh syndrome spectrum disorders. These conditions typically present with neurological and metabolic features reflecting mitochondrial energy failure. The biochemical characterization of each biosynthetic step helps clinicians and researchers interpret variants and understand disease mechanisms.

Primary coenzyme Q deficiency results from mutations in genes required for ubiquinone biosynthesis. Because GO:0160224 describes a specific catalytic step in this pathway, loss of the corresponding activity can contribute to reduced coenzyme Q levels. Patients may show variable clinical presentations, and biochemical assays of pathway intermediates can help localize the defect.

Mitochondrial diseases often involve impaired respiratory chain function. When coenzyme Q biosynthesis is disrupted, electron transfer from complexes I and II to complex III is compromised. Studying the activity defined by GO:0160224 in patient-derived cells or models can reveal whether this step is limiting and whether it represents a therapeutic target.

Direct measurement of GO:0160224 activity can be performed using mitochondrial fractions or recombinant enzyme preparations. Assays monitor NADH oxidation or oxygen consumption in the presence of the 5-methoxy-2-methyl-3-(all-trans-polyprenyl)benzoquinone substrate. Reaction products can be analyzed by liquid chromatography-mass spectrometry to confirm formation of the 3-demethylubiquinone. These assays are essential for linking genotype to biochemical phenotype.

Mass spectrometry-based metabolomics can quantify coenzyme Q intermediates in cells or tissues. By comparing wild-type and mutant models, researchers can identify which intermediates accumulate when the activity described by GO:0160224 is impaired. This approach helps localize the block within the biosynthetic pathway and provides biomarkers for coenzyme Q deficiency.

CRISPR knockout, point-mutation knock-in, and tagged knock-in models allow precise manipulation of candidate genes. These models can be used to test whether a specific gene is required for the activity, whether a patient variant is pathogenic, and whether the protein localizes correctly. Overexpression models complement loss-of-function studies by testing sufficiency.

Because coenzyme Q is required for respiratory chain electron transfer, mitochondrial function can be assessed using Seahorse extracellular flux analysis, oxygen consumption measurements, and ATP production assays. These readouts connect the activity of GO:0160224 to cellular energy metabolism and help evaluate rescue strategies.

Researchers studying 3-demethoxyubiquinone 3-hydroxylase (NADH) activity-related genes often need to determine whether a candidate gene is causally involved in coenzyme Q biosynthesis, whether a patient variant impairs catalysis, and how the pathway responds to genetic rescue. EDITGENE provides the CRISPR and cell-model tools required to answer these questions with publication-grade rigor.

GO:0160224, 3-demethoxyubiquinone 3-hydroxylase (NADH) activity, defines a specific catalytic step in coenzyme Q biosynthesis that uses NADH and O2 to hydroxylate a ubiquinone precursor. This activity is essential for mitochondrial function, and its disruption is linked to mitochondrial disease phenotypes such as the nuclear gene-encoded Leigh syndrome spectrum. Researchers can study this step using enzymatic assays, metabolomics, and CRISPR-based genetic models, and EDITGENE provides the tools needed to build these models efficiently.